| Combined targeting of the BRD4–NUT–p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734 CD Morrison-Smith, TM Knox, I Filic, KM Soroko, BK Eschle, MK Wilkens, ... Molecular cancer therapeutics 19 (7), 1406-1414, 2020 | 66 | 2020 |
| Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats CF Ferris, S Nodine, T Pottala, X Cai, TM Knox, FH Fofana, S Kim, ... Neurobiology of Pain 6, 100034, 2019 | 42 | 2019 |
| Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma X Zhang, T Zegar, A Lucas, C Morrison-Smith, T Knox, CA French, ... Oncogene 39 (24), 4770-4779, 2020 | 31 | 2020 |
| In search of early neuroradiological biomarkers for Parkinson’s Disease: Alterations in resting state functional connectivity and gray matter microarchitecture in PINK1−/− rats X Cai, JU Qiao, T Knox, S Iriah, P Kulkarni, D Madularu, T Morrison, ... Brain Research 1706, 58-67, 2019 | 26 | 2019 |
| Chemical screen identifies diverse and novel histone deacetylase inhibitors as repressors of NUT function: implications for NUT carcinoma pathogenesis and treatment H Shiota, AA Alekseyenko, ZA Wang, I Filic, TM Knox, NM Luong, ... Molecular Cancer Research 19 (11), 1818-1830, 2021 | 12 | 2021 |
| Abstract B014: Novel dual BET/p300 bromodomain inhibitors therapeutically inhibit BRD4-NUT driven NUT Carcinomas CD Morrison-Smith, A DiBona, E Walsh, K Danga, I Filic, T Knox, ... Molecular Cancer Therapeutics 18 (12_Supplement), B014-B014, 2019 | | 2019 |
| GNE-781 CD Morrison-Smith, TM Knox, I Filic, KM Soroko, BK Eschle, MK Wilkens, ... | | |
